Research Paper Volume 12, Issue 21 pp 21706—21729
Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways
Figure 5. Puerarin suppresses in vitro hydroxyapatite resorption activity of the osteoclasts. (A) Representative images show the total numbers of osteoclasts and the resorption pits formed in the hydroxyapatite resorption assay in the BMMs treated with 50 ng/mL M-CSF, 50 ng/mL RANKL and 0, 10, or 100 μM puerarin. (B) Hydroxyapatite resorption assay analysis showsthe total resorbed hydroxyapatite area in the BMMs treated with 50 ng/mL M-CSF, 50 ng/mL RANKL and 0, 10, or 100 μM puerarin. Note: n=3 per group; **P <0.01 vs. the control group (without puerarin treatment).